Analysts Have Conflicting Sentiments on These Healthcare Companies: Omada Health, Inc. (OMDA), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Omada Health, Inc. (OMDA – Research Report), Alkermes (ALKS – Research Report) and Apellis Pharmaceuticals (APLS – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Omada Health, Inc. (OMDA)
In a report released yesterday, Craig Hettenbach from Morgan Stanley maintained a Buy rating on Omada Health, Inc., with a price target of $32.00. The company’s shares closed last Monday at $16.12, close to its 52-week low of $14.14.
According to TipRanks.com, Hettenbach is ranked #3038 out of 10398 analysts.
Currently, the analyst consensus on Omada Health, Inc. is a Strong Buy with an average price target of $27.00, implying a 72.6% upside from current levels. In a report issued on January 5, Barclays also maintained a Buy rating on the stock with a $22.00 price target.
See the top stocks recommended by analysts >>
Alkermes (ALKS)
In a report issued on January 8, Leonid Timashev from RBC Capital maintained a Buy rating on Alkermes, with a price target of $47.00. The company’s shares closed last Monday at $29.62.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alkermes with a $46.17 average price target, a 56.1% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $44.00 price target.
Apellis Pharmaceuticals (APLS)
RBC Capital analyst Lisa Walter maintained a Hold rating on Apellis Pharmaceuticals on January 8 and set a price target of $22.00. The company’s shares closed last Monday at $23.20.
According to TipRanks.com, Walter is a 2-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $43.25.
